Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

SA Transcripts159.03K FollowersFollow5ShareSaveCommentsQ4: 2026-03-18 Earnings SummaryPlay CallPlay Call10-KEPS of $0.06 beats by $0.16 | Revenue of $718.00K (844.74% Y/Y) beats by $655.40K Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call March 18, 2026 8:30 AM EDT Company Participants Victoria Fort - Senior Vice President of Corporate Affairs & Corporate StrategyMeg Alexander - CEO, President & COOJeffrey Rona - Chief Business & Financial Officer and Corporate Secretary Conference Call Participants Laura Chico - Wedbush Securities Inc., Research DivisionAlyssa Larios - Leerink Partners LLC, Research DivisionMyles Minter - William Blair & Company L.L.C., Research DivisionFrançois Brisebois - LifeSci Capital, LLC, Research DivisionMadison Wynne El-Saadi - B. Riley Securities, Inc., Research DivisionJay Olson - Oppenheimer & Co. Inc., Research DivisionRitu Baral - TD Cowen, Research Division Presentation Operator Good afternoon, everyone. My name is Angela, and I will be your conference operator today. At this time, I would like to welcome you to Ovid Therapeutics business and pipeline update call. This conference is being recorded. [Operator Instructions] At this time, I would like to turn the call over to Victoria Fort. Please proceed. Victoria FortSenior Vice President of Corporate Affairs & Corporate Strategy Thank you. Good morning, everyone, and thank you for joining us. Earlier today, we issued a press release announcing business and pipeline updates, and financial results for the 3 months and full year ended December 31, 2025. A copy of the release can be found in the Investor Relations tab on our corporate website, ovidrx.com. As a reminder, during today's call, we'll be making forward-looking statements. Various remarks we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements. for the purpose of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this call are subject to a number of risks and uncertainties which could cause our actual results to differ materially from those expressed or